It is an incredible delight and a respect to stretch out our warm welcome to go to the Global Experts Meet on Advanced Technologies in Diabetes Research and Therapy on November 11-12, 2019 in San Francisco, USA, which incorporates incite keynote introductions, oral talks, and Poster Presentations.
· Diabetes Research fellows
· Diabetes Health Professionals
· Diabetes Device industries
· Medicare Associations
· Healthcare Associations
· Medical colleges
· Academic researchers
· Research Institutes
· Endocrinology Societies & Associations
· Diabetes Societies & Associations
· Pharmaceutical Companies
· Diabetes & Metabolism students, Scientists
· Diabetes & Metabolism Researchers
· Diabetes & Metabolism Faculty
· Diabetes & Metabolism Associations and Societies
· Business Entrepreneurs
· Training Institutes
· Manufacturing Medical Devices Companies
Scientific Session 1:
Diabetes ResearchResearch is a creative and systematic work undertaken to increase
the knowledge of humans, culture and society. Research plays a key role in
establishing or confirming facts, reaffirm the results of previous work, solve new or existing problems, support theorems, or develop new theories.
Research in terms of diabetes is a vast subject as it is one of the most common diseases in the world. Diabetes research has increased greatly in this new medical era. A wide range of research is going on day to day specially on cure, prevention and management of diabetes. Researchers are eager to improve the diagnosis and therapy of diabetes using advanced technologies in the field of medicine.
The main aim of diabetes research is to detect the overall condition of diabetes with the help of numerous clinical case studies and research studies including animal models and human models. The advancement in science and technology has discovered the expansion of newer generation of medicine in drug discovery. Documentation and clinical investigation of bio-active ingredients have reworked the investigation of drug discovery and lead identification for diabetes control.
The main aim of the on-going diabetes research is to re-investigate the mechanisms in depth and provide integrated care for diabetes. In spite of scientific innovations and better healthcare amenities, diabetes continues to be burden in varied segments, particularly in case of middle and low-income countries.
The technology in medical research has been advanced specially in nano-medicine which includes smart drugs that only activate when needed, nano-formulations for efficient drug delivery, engineered microbes which produce human hormones, and even nano-robots, which would move autonomously around the body acting as a booster, for our immune system, red blood cells, or many other biological systems.
· Emerging Focus in Diabetes Research
· Diabetes Clinical research
· Diabetes Case study
· Translational Research
· Diabetic Nano medicine Research
· Research on Insulin
· Drug Research and Development
· History and scope of Diabetes Research
· IPR and socio issues in diabetes research
2: Diabetes TherapyAlthough diabetes has been known since antiquity,
the treatments have been known thoroughly,
since the 21st century. Diabetes therapy has been updating day to day along
with the research. There are different types of therapies involved in diabetes treatment. Complimentary and alternatives methods are also
being improved in recent years. Diabetes is a condition or a state of an
individual which can’t produce sufficient insulin. Hence in olden days the research and therapy have
completely done on Insulin. But in this new medical era, the
scope of diabetes research and therapy has improved and new therapies have been
introduced such as pancreatic islet
transplantation, Bariatric surgery,
Embryonic Stem Cells, Mesenchymal Stem Cell Therapy, Gene
therapy. Along with these scientific therapies Indian and Chinese cultures have had several
thousand years of experience and history in diabetes prevention and treatment
by using traditional and herbal medicine is
involved widely in diabetic research and therapy specially Holistic medicine, Naturopathy, Ayurveda, and many such therapies. Nutrition therapy will have its greatest impact
when a person is first diagnosed with diabetes.
Apart from these therapies, there are new innovations in relation to laser and gases. Laser treatment is used to treat different diabetic complications such as diabetic wound healing, cancer in diabetes patients, diabetic retinopathy. Ozone is a gas, which can be used in the treatment of ulcers in diabetes patients, which can be delivered with ozonized oils such as ozonized sunflower or olive oil, or by a mixture of oxygen and ozone that directly applied to the wound, or through rectal insufflation.
· Alternative and Complementary Therapies
· Cellular-based therapy
· Hormonal Therapy
· Gene therapy in diabetes
· Insulin & Non-Insulin therapy
· Pancreatic Enzyme Replacement Therapy
· Proton / Laser Therapy
· Mind-Body & Yoga Therapies
· Pharmacological therapies
· Ozone-Oxygen Therapies
· Diabetes Statin therapy
· Nutritional therapies
· Bariatric surgery versus intensive medical and conventional therapy
· Different Drug therapies
· Fluid & electrolyte therapy for Endocrine disorders
3: Diabetes MedicationAnti-Diabetic
Medications work by two mechanisms either lowering blood glucose level or by
increasing sensitivity to insulin. In the case of Type 1 Diabetes, there
is a lack of insulin production hence; insulin must be administered subcutaneously. Where
in Type 2 Diabetes it can be treated by oral hypoglycemic agents which act either by increasing
the amount of insulin secretion by the pancreas or by increasing the sensitivity
of target organs to insulin or by decreasing the rate of absorption of glucose in the gastrointestinal tract.
Insulin is the initially invented medication and one of the most used diabetes medication. People can self-inject insulin under the skin if hospitalized a doctor/nurse might inject insulin directly into the blood. And it is also available as a powder so that people can breathe in. Insulin injections of different based on how quickly they act, their peak action, and how long they can last. There are several different types of insulin-like Rapid-acting injections that take less time to show effect i.e within 5 to 15 minutes but lasts for a shorter time period of 3 to 5 hours, Short-acting injections take 30 minutes and 1 hour time to show effect and last for 6 to 8 hours, Intermediate-acting injections that take about 1 to 4 hours to show effect and last for 10 to 26 hours, finally Long-acting injections show effect after 1 or 2 hours and last for between 14 and 24 hours. There are Premixed injections, combinations of the different types of insulin mentioned above. All show an effect in 5 minutes to 1 hour and last for 10 to 24 hours.
Other than insulin there are many other oral antidiabetic medications which are non-insulin injectables in the market. They include Biguanides, Sulphonylureas, Meglitinides, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Incretin Agonists and a variety of products that combine some of the drugs mentioned above are available to treat diabetes.
The medication of the diabetic patients varies from the patient to patient based on different factors like the health condition and type of diabetes they are suffering from. For instance, in diabetic complications, the medication will be prescribed based on the complications of patients like cardiovascular issues, hypertension, obesity etc. Based on types such as gestational diabetes, neonatal diabetes, pediatric diabetes. It also varies based on the age factor of the patients.
· Insulin Medication
· Non-insulin Medications
· Diabetes Oral Medications/Anti-Diabetic Medications
· Diabetic Complications and related medications
· Factors considered in selecting proper medications.
· Bio availability and bio equivalence of drugs in diabetic patients
4: Biomarkers and Biosimilars in DiabetesBiomarker is a naturally occurring
molecule/gene/a character that helps in identifying the diseases. Biosimilars are
biological medical products/molecules which are almost identical copies of an
original product manufactured by different companies and an already
FDA-approved biological product, referred to as a reference product. Human bio monitoring (HBM) is
a tool of health-related environmental monitoring.
Diabetes is a major lifestyle disease, It is necessary to identify potential biomarkers associated with diabetes for early detection and proper management of diabetes. Biomarkers are known as signature molecules or molecular markers or biological molecules found in blood, tissues and other body fluids. Biomarkers are used to monitor how well the body is responding to a particular disease. Hemoglobin A1c is considered as a biomarker for the presence of Diabetes Mellitus. Application of biomarkers in the development of anti-diabetic drugs will depend on understanding of the pathogenesis of diabetes.
The development of Biosimilars must be proven to be comparable almost to the reference product and so that less clinical trials are required, reducing the expense of the drugs and accelerating the approval. In diabetes research for the first time Biosimilar is the first biosimilar-insulin (Basaglar) was introduced in the U.S in 2016. A year prior to Basaglar, Europe introduced it in the name of Abasaglar. Basaglar was manufactured by Boerhringer Ingelheim and Eli Lilly. It was proven to be similar in function, efficacy and safety to the brand name insulin glargine, long-acting insulin manufactured by Sanofi. But Basaglar is technically not considered a biosimilar by the FDA in U.S. because glargine products are not licensed under Public Health Service Act, although it meets the criteria of a biosimilar product, while it is considered as such in Europe.
In human biomonitoring, human body fluids and tissues are examined for contamination with pollutants for example; the levels of mercury in the blood or urine individuals or populations are analyzed. Human biomonitoring plays a key role in environmental health and the assessment of pollution levels in the population, population groups or individuals.
· Biomarkers in diabetes
· Biosimilars in diabetes
· Scope and Role of Biomarkers
· Biomarker Application in diabetes research
· Novel Biomarkers
· Biosimilar Development, Review, and Approval
· Biosimilar and Interchangeable Products
· Prescribing Biosimilar and Interchangeable Products
· Biosimilar Product Information
· Human Biomonitoring
5: Emerging Technologies for Diabetes CareDiabetes is a serious issue which
is still uncured and makes new research, in treatment and management techniques is a crucial necessity. Over the
past years, there have been considerable breakthroughs in preventing diabetic complications by
understanding them. Modern diabetes technologies are becoming
ever more sophisticated globally.
While some research is focusing on technology-based treatments like generating artificial pancreas or engineering insulin-producing beta cells, some other researches are directed towards finding long lasting new drug molecules, devising more efficient diets and developing intensive treatment programs. Needless to say, trends and advances in diabetes research is the need for bringing excellent management of this serious life-threatening disease.
The Artificial Pancreas Device is an arrangement of gadgets which nearly emulates the glucose directing capacity of the pancreas. This is not only used for screening glucose levels but naturally alters the conveyance of insulin to lessen glucose levels in hyperglycemic condition and also limit the frequency of low blood glucose levels in hypoglycaemic conditions with practically zero contribution from the patient.
Nanotechnology another advanced technology of medicine which is globally researched a new and innovative medical technology. Nanotechnology in diabetes is the advancement of novel glucose estimation and insulin conveyance modalities that hold the possibility to drastically enhance the personal satisfaction for diabetics. Nano-medication is typically 10-100 times littler than a body's phone yet just minimal bigger than particles makes conceivable the treatment of the starting point of diabetes at the atomic level.
Technology has developed highly especially in the scientific and medical fields. Now a day’s even common people can have a minimum knowledge of any disease and its treatment. Many medical services and software technologies like telemedicine have been introduced.
· Nanotechnology in diabetes
· Artificial organ transplantation technology
· Human Recombinant Insulin
· Digital Healthcare: Designing the Digital Solution
· Clinical Research Informatics helps in Effective Data Collection
· Advanced Medical Technologies to Be Used in Hospitals
· Blood Glucose Monitoring and Glycemic Control in the Hospitals????
· Computerised applications in Diabetes mitigations
· Informatics in the Service of Medicine, Telehealth, Telemedicine, Software and other Technologies
· Clinical Decision Support Systems/Advisors
· Securing funding for diabetes technology
6: Medical Devices used in Diabetes
TreatmentMost common medical devices used
in diabetes diagnosis and
treatment include blood-glucose meters, insulin pens, insulin pumps. These
devices include glucose ministering devices, Bioartificial pancreas, insulin
delivery systems, and insulin administrating systems. And many diabetes monitoring and
diagnostic devices like lancets, analog glucose monitor, test
Strips, Syringe, Injectors also come under this. And these
devices are designed to be feasible to use and painless in the insertion. Some companies
are joining up and put their efforts to create a contact lens that measures the glucose in tears.
Researchers have developed a pill with hollow needles which can inject a drug directly into the stomach lining. Once the capsule has been swallowed, its outer coating will be dissolved. This approach is still in its infancy, but it could provide another new way to deliver insulin.
As the number of diabetic patients increasing globally, the market for diabetes care devices is rapidly expanding, and medical device companies are investing in more innovative solutions which aim to make patients’ disease management less demanding.
· Insulin pumps /insulin infusion systems
· Insulin Pens and novel Insulin delivery techniques
· Tear glucose monitoring contact lenses
· Continuous glucose monitoring (CGM)/ Blood Glucose Meters
· The future: the Artificial Beta Cell
· Artificial pancreas
· New Insulin Analogues
· Blood glucose monitoring: Glucose pumps & sensors
· Intravenous blood glucose monitoring systems
· Insulin dose calculation software
· Flash Glucose Monitoring.
· Closed-loop system and algorithm
· New insulin delivery systems: Inhaled, transdermal patches, and implanted devices
Scientific Session 7: Diabetes ManagementNutrition plays a leading role all over the world in treating the patients with Diabetes. Healthy eating is a cornerstone of healthy living, irrespective of individuals with or without diabetes but if you are having diabetes, you need to know how diet affects your blood sugar levels. It's not only matter of type of food you eat but also quantity you eat and the combinations of food you eat. Have to Learn about carbohydrate counting and portion sizes and make sure that every meal is well-balanced. Apart from this have to coordinate the meals and medications. Diabetes management works on to bring the carbohydrate metabolism to normal state. In order to achieve it in patients with insulin deficiency by using insulin injections or pumps and in patients with insulin resistance are treated with exercise and proper diet maintenance. The best way to have a healthy living with or without diabetes is maintaining a healthy diet.
Diabetes is a main factor for cardiovascular diseases and development of other secondary conditions. Regular check-ups on cholesterol, blood pressure, HDL, LDL & triglyceride levels, and eye examination to prevent diabetic retinopathy, foot care specialist is to prevent diabetes occurrence. And the other complications caused due to other diseases such are obesity, cancer are to be treated or prevented.
Physical activity is another important part of diabetes management. When you do exercise, your muscles use glucose for energy by this regular physical activity helps your body to use insulin more efficiently. There are many regular factors work together to lower your blood sugar level. The more you work out, the longer the effect lasts. Even light activities such as gardening, housework, being on your feet for extended periods can improve your blood sugar.
· Self-management of diabetes – Regular glucose monitoring, self-medication, regular clinical check-up’s.
· Lifestyle management of diabetes – Exercise, alcohol, stress
· Diabetic Diet Management- Food, micronutrients
· Clinical care management of Diabetes - Medication
· Management of Neonatal and Pediatric diabetes
· Management of Gestational Diabetes / Menstruation and menopause (Diabetic women)
· Management of Diabetes hypertension / blood pressure
· Management of Diabetic Cardiovascular Diseases
· Management of Diabetic Eye Diseases
· Management of Diabetic Kidney Diseases
· Management of Diabetic Foot Diseases
· Management of Neuro Diabetes
· Management of Diabetes obesity
Session 8: Diabetic psychological careThe importance of the psychological state consultants in the management of medically ill individuals has grown with the proliferation of information linking health and behavior. Evidence demonstrating the importance of psychological care in diabetes has been accumulating for more than 20 years and the role of the Psychiatrist in diabetes care has expanded accordingly.
People with diabetes experience disproportionately high rates of mental health issues such as anxiety, depression and eating disorders. Most of the studies state that people with diabetes must have access to psychological treatment and support in order to reduce psychological distress and improve self-management.
The psychologist provides direct services to the patient via promotion of health behaviors and treatment of psychological problems. They also provides consultation to the medical team regarding how to incorporate psychological principles into patient care to enhance clinical outcomes. The bulk of the psychological services especially in diabetes care are provided to patients who do not have diagnosable psychological problems.
· Diabetes Psychological care
· Role of the Psychologist in Diabetes
· Psychosocial Factors in Diabetes Care : emotional factors, social factors, behavioral factors
· Psychopathology in Diabetes
· Emotional and psychological needs for diabetic individuals.
· Psychosocial Issues Unique to Children and Adolescents
Scientific Session 9: Diabetes SurgeryDiabetes is an epidemic health problem, affecting over 150 million people all over the world. This number is expected to be double in the first decades of the third millennium. Although diabetes is traditionally viewed as a chronic and relentless disease in which delay of end-organ complications is the major goal in treatment, bariatric surgery offers a novel endpoint: complete disease remission or major improvement.
Recent advancements in diabetes care include surgeries in addition to behavioral and medical treatments. Surgery should be an accepted option in people who have type 2 diabetes mellitus and with Body Mass index of 35 or more. Surgery has to be considered as an alternative treatment option for patients with a BMI between 30 and 35 when diabetes mellitus can’t be adequately controlled by optimal medical regimen, especially in the presence of other major risk factors such as cardiovascular disease. Surgery for diabetic individuals must be performed within accepted guidelines which include an on-going multidisciplinary care, patient education, follow-up, and clinical audit, as well as effective and safe surgical procedures.
Bariatric surgeries constitute a powerful option to ameliorate diabetes in patients affected by obesity severely. Bariatric surgery is an appropriate treatment for people with Type 2 Diabetes and obesity not achieving recommended treatment targets with other medical therapies and also very cost - effective. The risk of complications and death with bariatric surgery is low and similar to that of well-accepted procedures like gallbladder surgery, metabolic surgery.
Novel operations are geared towards the treatment of diabetes and are not necessary to induce weight loss. In addition to the normal Risks of Surgery, diabetics face additional risks to undergo any surgical procedure. These risks are heightened if you have had diabetes for an extended period of time or frequently have high blood sugars or if you are having difficulty in controlling your glucose level. Patients, who have already faced and experienced major complications from diabetes, like neuropathy or requiring an amputation are also at higher risk.
After surgery, the need for high-quality nutrition and regular tight glycemic control continues. Nutrition will provide the building blocks for proper healing and a normal glucose level will promote a quicker return to good health. Tight management of glucose levels may probably shave days or even weeks off of your recovery period compared to recovery times with elevated blood glucose levels.
· Diabetes Surgery: A New Discipline?
· Diabetes and Bariatric Surgery
· Diabetes and Metabolic surgeries
· Diabetes and Sleeve gastrectomy
· Diabetes and Heart / Vascular Surgery
· Diabetes organ transplantation / organ removal surgery
· The Risks and complications of Surgery for Diabetics
· Factors to be considered in surgery to diabetes patients.
· Diabetes Surgery: Opportunities, Barriers, and Limitations
· Diabetic parameters in diabetes surgery: Rate of glucose levels
· Diabetes care and management after Surgery
Scientific Session 10: Diabetes: Health Education & Health PromotionHealth education is a combination of learning experiences designed to help individuals or communities improve their health, by increasing their knowledge or influencing their attitudes, by focusing on prevention. Diabetes education will reduce the costs that individuals, families, insurance companies, medical facilities, communities, the state, and the nation would spend on medical treatment.
Health promotion is the process of enabling people to increase control over and to improve their health, it moves beyond a focus on individual behavior towards the wide range of environmental and social interventions.
Historically, Centers for Disease Control and Prevention’s (CDC’s), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) has provided funding for state chronic disease programs for specific chronic conditions and risk factors, releasing a separate funding opportunity for announcements (FOAs) to address diabetes, cardiovascular disease, and obesity. However, chronic diseases have a high incidence of comorbidity, and the burden of these diseases has continued to increase.
Awareness of various aspects of Diabetes is essential for the prevention, control, and management of the disease. However, several studies have consistently written that awareness of Diabetes in the general population is low.
Awareness + Education is more powerful cure for diabetes and many such chronic diseases. Knowing symptoms of type 1 diabetes, will be life-saving when a diagnosis is right around the corner. If you’re at the risk for type 2 diabetes, education can help to prevent or delay the progression of the disease. Education helps our communities offer support instead of blame through a very challenging disease is invaluable. It’s only by raising awareness that we can help everyone else to understand what we live with and how to be health in diabetes.
· Concept of health education & health promotion in diabetes
· National Diabetes Prevention Programs
· Public Awareness Campaigns
· Promotional Initiatives – Webinars, Books & Publications
· Complete diabetes awareness
· Role and importance of diabetes education & promotion
· Health promotion strategies
· Basic principles of health education
Scientific Session 11: Pharmacoeconomics in diabetesPharmacoeconomic evaluations have grown to be a crucial tool in therapeutic decision making especially in chronic diseases such as diabetes, where there are limited resources. Pharmacoeconomic research is the process of identifying, measuring and comparing the costs, risks and benefit of services, therapies and determining which alternatives can produce the best health outcomes for resource invested. The economic burden of diabetes on patients, institutions and society in the form of direct and indirect costs is enormous in the world. Diabetes mellitus patients require frequent monitoring of blood glucose levels, anti-diabetic drugs on a chronic basis and all of which result in a significant economic burden on the diabetes patients and the world economies.
In recent decades there is widely documented and recognized increase in diabetes prevalence, not only in high-income countries but also in low- and middle-income countries. The economic burden associated with diabetes is less clear. The studies indicate a varied economic burden of diabetes, most directly affecting patients. The magnitude of the cost estimates differs considerably between and also within the countries, calling for the contextualization of the study results. Scope remains large for adding to the evidence based on labor market effects of diabetes in the world. Further, there is a need for future studies to incorporate more advanced statistical technologies in their analysis to account for possible biases in the estimated costs.
Diabetes with complications results in double the cost when compared to diabetes alone, so that the burden of diabetes and its complications was significant for an individual. This cost associated with the disease is preventable by diet restriction and aerobic exercise, to reduce the prevalence of diabetes and its complications in mind. To avoid increased medical cost, early detection of complications through appropriate screening is most liable way, such as adequate control of blood sugar, blood pressure, cholesterol with proper diet restrictions, and some lifestyle modification is important.
· Pharmacoeconomics: Principles, Applications: Introduction
· Pharmacoeconomic challenges in the management of diabetes
· Methods of Pharmacoeconomics
· Humanistic Evaluation Methods
· Pharmacoeconomic Controversy
· Pharmacoeconomic Consequences
· Drug Therapy Evaluation
· Clinical Pharmacy Service Evaluation
· Naturalistic pharmacoeconomic studies
· Strategies to Incorporate Pharmacoeconomics into Pharmacotherapy
Scientific Session 12: Pharmacogenetics & Pharmacogenomics: DiabetesGenomic studies have greatly advanced our understanding of the multifactorial aetiology of diabetes especially in type 2 diabetes (Diabetes Mellitus) as well as the multiple subtypes of monogenic diabetes mellitus. Pharmacogenetics is the study of interaction between genetic variation and drug exposure on modulating therapeutic response. Pharmacogenetic research mainly focuses on the study how genetic variation may influence drug efficacy and/or toxicity; pharmacogenomics expands this quest to the complete genome. Pharmacogenetic findings may help to uncover new drug targets, clarify disease heterogeneity, illuminate pathophysiology, aid in the fine-mapping of genetic associations, and contribute to personalized treatment.
In diabetes, there is exemplar for the successful application of pharmacogenetic concepts into monogenic forms of diabetes, such as maturity onset diabetes of the young or neonatal diabetes. Whether similar insights will be produced for the common form of diabetes mellitus remains to be seen. With recent advances in genetic approaches, the successive application of candidate gene studies, genome-wide association studies and large-scale genotyping studies has begun to generate suggestive results which may lead to changes in clinical practice. However, many potential barriers in the translation of pharmacogenetic discoveries to the clinical management of diabetes are still remain. These studies focus on a few feasible candidate genes involved in drug pharmacodynamics / pharmacokinetics, or those associated with Type 2 diabetes as a disease phenotype.
Here in relation to diabetes the main focus is on mostly used drugs in diabetes treatment such as sulfonylureas, metformin and thiazolidinediones (troglitazone, pioglitazone, and rosiglitazone). However, the pharmacogenomics studies in response to anti-diabetic drugs for Diabetes Mellitus has yet to be translated into clinical practice, although some moderate genetic effects have now been described that merit follow-up in trials in which patients are selected according to genotype are still going.
· Pharmacogenomics of Drug Response in Type 2 Diabetes
· Patient stratification: sulfonylureas in monogenic and polygenic diabetes
· Goals of pharmacogenetic studies
· Neonatal diabetes: mutations in ABCC8 or KCNJ11
· Target identification: the elusive molecular target of metformin
· Pharmacogenomics of Antidiabetic Drugs
· Candidate genes
· The impact of genetic variants on metformin response
· Genome-wide association studies
· Large-scale genotyping studies
· Translating pharmacogenetic information into clinical practice
· Functional characterisation: TCF7L2 and pharmacogenetics as a discovery tool
Scientific Session 13: Global Market for Diabetes and its ResearchGlobal diabetes market is expected to expand at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is separated on the basis of type of diabetes, drugs classification and diabetic devices used. Diabetic drugs have the highest market shares amongst drugs and devices compared to other and are also expected to have the highest rate in growth with a CAGR of 8.9%. Some of the top selling diabetic drugs include Januvia (Merck And Co), Humalog (Eli Lily And Co), Lantus (Sanofi), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) Victoza (Novo Nordisk), Janumet (Merck And Co.), and Galvus (Novartis). With the diabetic population it is expected to cross the 350 million market by 2030 the market is expected to show growth rate strong. Diabetic drugs are highly priced it would be one of the major drawbacks.
Diabetic devices include insulin delivery devices and blood glucose meters. The market for blood glucose meters is having the top market shares compared to the insulin delivery systems such as syringes and injection pens. Continuous glucose monitoring systems is also having the highest market growth. Meter and strips are one of the most expected to dominate the overall market share in diabetic devices.
Overall market is driven by growing burden of diabetes on country economies. U.S. alone spends almost 11% of its health expenditure only on diabetes. India and China are most affected by diabetes with over 120 million patients and majority of diabetes patients are either undiagnosed or left with the lack of basic treatment. The impending unmet needs are forcing the governments and companies to provide basic needs for diabetes individuals.
Research and development is on-going to development long term solution for prevention and cure of diabetes. Some of the leading manufacturers are trying to develop artificial pancreas in the part of diabetes research and therapy field. At present mostly CGMS devices are being used with insulin pumps as secondary prototype for artificial pancreas. It is estimated that artificial pancreas research studies will be ready for commercialization by next decade. Development of advanced technologies in the field of diabetes research and therapy will be a major boost for the market.
Apart from prevention and treatment, it is important to manage diabetes as efficiently as possible. Diabetes Management mainly aims to minimize the risk of long-term consequences associated with diabetes. It not only involves keeping a check on blood glucose, blood pressure, and cholesterol levels but also focussing on modern approaches like exercise, diet and lifestyle management often coupled with on-going blood glucose level monitoring. Self-management of diabetes is also another crucial thing for proper adherence to dietary and lifestyle modifications.· Global Demographics & Market Dynamics
· Comprehensive research methodology of Diabetes market
· Macro and micro factors influencing the Diabetes market
· Analysis of regional regulations
· Market Segmentation: By Devices, By Diabetes Types, By Drug Classes, By End-User, By Geography
· Insights about market determinants
· Global Challenges and Unmet Needs
· Comprehensive research methodology of Diabetes market
· Market Dynamics
· Market Ecosystem
· Currency and Limitations
Abstract Submission & Registration
You are warmly welcomed
to project your ground-breaking works through an enchanting speech at Global Experts Meet on Advanced Technologies in Diabetes
Research and Therapy.
We feel extremely thankful and honoured for your consent to be an active
participant in our conference as a speaker. Submit your abstract
online at Speaker abstract. Young Researcher Sessions are organized at the Diabetes Meet 2019, to provide a unique platform for Young Researchers / Investigators for presenting latest research projects with an in-depth analysis. Allied Academies cordially invites Young Researchers from Universities/Institutes/Industries to present a short oral presentation during the forum. These oral presentations should be of 10 minutes duration in related scientific track followed by 5 minutes question hour. Therefore, presenters are encouraged to give comprehensive and dynamic talks. Applications will be selected based on past research productivity and future promise.
Come Let’s Bring a Transformation in the Scientific Society!!
The Young Researchers Forum offers young researchers the possibility to meet and discuss research topics and methodologies, share and develop ideas, learn from each other and gain knowledge from senior researchers.
The abstracts can be submitted online under Submit Abstract in homepage or through e-mail at email@example.com
Register Here: Diabetes Meetings Registration
Europe: The number of people living
with diabetes in Europe is expected to increase from 52 million in 2014 to 68.9
million by 2035, according to the International Diabetes Federation (IDF).
Across Europe, around 1 in 11 adults is affected and this number is set to rise
as the population ages.
USA: Diabetes Mellitus has been
growing at an exponential rate and World Health Organization (WHO) estimates
that the diabetic population is likely to reach 366 million in 2030. The United
States is expected to have an increase of 102 percent in the diabetic epidemic
in 2030 when compared to 2000.
Middle East: The rate of diabetes in
parts of the Arabian Peninsula is over twice the global average rate, and much
higher than some other areas of the Middle East and North Africa (MENA). And
cases of type-2 diabetes outnumber cases of type-1 diabetes by a ratio of 10:1.
Asia Pacific: The Asia-Pacific Diabetes
Care Devices Market has been estimated at USD 2.461 Billion in 2015 and is
projected to reach USD 3.518 billion by 2020, at a CAGR of 7.41% during the
forecast period from 2015 to 2020.
San Francisco is the cultural, commercial, & financial
center of Northern
California which is the 13th most populous city in the United States, and
the 4th most populous in California. San Francisco is known for its cool summers, fog, steep
rolling hills, eclectic mix of architecture, and landmarks, including the Golden
Gate Bridge, Fisherman's Wharf, cable cars, Alcatraz Federal Penitentiary,
and its Chinatown district. It is home to a number of educational and cultural
institutions like the University of San Francisco (USF), San Francisco State
University (SFSU), University of California, San Francisco (UCSF), the De
Young Museum, the California Academy of Sciences and the San Francisco
Museum of Modern Art and many more tourists’ attractions. The
impact of diabetes on the individual quality of life and the general economy in
Italy is substantial. Healthcare costs for patients with diabetes in Italy are
estimated at approximately €5.5 billion annually, representing more than 6% of
total national healthcare spending. The Cost of Diabetes
in Europe—Type 2 Study (CODE-2), which measured the total healthcare costs
for patients with type 2 diabetes in 8 European countries (Italy, Belgium,
France, Germany, Netherlands, Spain, Sweden, and UK), found the total yearly
(1998) costs for people with type 2 diabetes in Italy alone to be almost €5.2
billion, a per-patient expenditure of at least €2900. Among patients with type
2 diabetes in Italy examined by the CODE-2 study, 17.8% were hospitalized
during the 6-month study, with an average hospital stay of 13 days. The cost of
hospitalizations accounted for the greatest portion of total costs for all
countries in the study, at 55%, leading non-anti diabetic drugs (21%),
outpatient care (18%) and anti-diabetic drugs (7%).Among non-anti diabetic
drugs, the majority were cardiovascular
and lipid-lowering (42%).Annual per-patient costs vary widely with primary
treatment type, with the highest per-patient costs accrued by those treated
with diet and exercise alone. Scientists
are starting to get energized again that a cure or close cure treatment could
come as right on time as inside the following decade or two. A diabetes immunization
diabetes antibody is
reliably being explored to give a genuine organic cure to T1 diabetes.
The point is for an immunization to be made that prevents the invulnerable
framework from assaulting the body's insulin-delivering
beta cells. Another cure prospect picking up force is islet cell
embodiment, with foundational microorganisms used to make insulin-creating
cells that can work without invulnerable framework impedance. Research into a
diabetes antibody is being made on a few fronts, with Selecta Bioscience, a
clinical bioscience organization, building up a Synthetic
Vaccine Particle (SVP) as an immunotherapy for T1 diabetes. The
immunization is required to reinvent the invulnerable framework to forestall
fiery reactions to insulin cells, with Selecta at present trailing SVP on mice
graciousness of financing from JRDF, a main worldwide association subsidizing
sort 1 diabetes investigate. Somewhere else, the Faust man Lab at Massachusetts
General Hospital is at present driving a human clinical trial program to test
the effectiveness of their Bacillus-Chalmette-Guerin
(BCG) antibody. Positive outcomes have just been accounted for from their Phase
I think about. A joint inflammation sedate, abatacept, has likewise indicated
it can defer sort 1 diabetes movement a year after treatment has been
suspended, with ponders again supported as a major aspect of JRDF's Restoration
a time of research plainly recommends that insulin creating cells might be
gotten from immature microorganisms. However, there is a requirement for
promote the improvement of strategies for separation and choice of totally
utilitarian cells. The recovery of cells is conceivable by controlling the
direction of different variables. Investigation of these cell control pathways
would be consistent steps towards the therapeutic endeavours in diabetes
treatment. Regardless of the accomplishments and advance with the
undifferentiated cells, the key issues like wellbeing concerns, teratoma
arrangement, transplantation issues and immune system reaction, and moral
situations of ESCs confine their further investigation in clinical trials.
Also, the issues related with the scale-up generation, hamper the investigation
of grown-up undifferentiated cells and iPSCs to be utilized as a decision of
helpful assets. The logical exertion of a previous decade empowered us to
deliver insulin discharging cells and the future years may concoct the answers
for utilize foundational microorganisms as a helpful specialist to cure diabetes. The
prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in
2000 and 4.4% in 2030. The total number of people with diabetes is projected to
rise from 171 million in 2000 to 366 million in 2030. The prevalence of
diabetes is higher in men than women, but there are more women with diabetes
than men. The urban population in developing countries is projected to double
between 2000 and 2030. The most important demographic change to diabetes
prevalence across the world appears to be the increase in the proportion of
people >65 years of age. These findings indicate that the “diabetes
epidemic” will continue even if levels of obesity remain
constant. Given the increasing prevalence of obesity, it is likely that these
figures provide an underestimate of future diabetes prevalence.The
number of people with diabetes has risen from 108 million in 1980 to 422
million in 2014. The global prevalence of diabetes among adults
over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. In 2012, an
estimated 1.5 million deaths were directly caused by diabetes and another 2.2
million deaths were attributable to high blood glucose. Almost half of all
deaths attributable to high blood glucose occur before the age of 70 years1.
WHO projects that diabetes will be the 7th leading cause of death in 2030.Diabetes Meet
2019 will feature the latest developments in research, diagnosis and
prevention and management of diabetes, new insulin analogues and new
technologies and devices for diabetic prevention, and for treating obesity and
many more. Not only will this innovative conference enhance your practical and
theoretical knowledge, it will provide you with the unique opportunity to
network with a wide range of professionals in the field of diabetes technologies and treatments. Global
Experts Meet on Advanced Technologies in Diabetes Research and Therapy includes
the renowned scientists, geneticist, microbiologists, doctors, professors,
public health planners, physicians, dieticians, pharmacists, students under the
of diabetes, industrial delegates and those using bioinformatics tools for
studying under the single roof. The following are the data of audience:·
association in the world plays a vital role and their mission is to prevent and
cure diabetes and to improve the lives of all people affected by disease. There
are many associations playing a role in prevention worldwide as well as in
countries.Major Diabetes Associations
around the Globe:·
Austrian Diabetes Association
Flemish Diabetes Association·
Association of Juvenile Diabetes
Canadian Diabetes Association·
Juvenile Diabetes Foundation of Chile
Diabetological Colombian Federation·
Croatian Diabetes Association
Union of Diabetics of Czech Republic·
Estonian Diabetes Association
American Association of Clinical Endocrinologists·
American Diabetes Association
Centers for Disease Control: Division of
Diabetes Advocacy Alliance
Diabetes Hands Foundation·
Juvenile Diabetes Foundation
National Kidney Foundation·
National Institute of Diabetes and
Digestive and Kidney Diseases
International Diabetes Federation·
Diabetes Association of Atlanta
University of Oxford
University of Cambridge·
Johns Hopkins University
University of California, Los Angeles
Imperial College London
University of Melbourne·
are a number of different types of diabetes drugs - with
some having similar ways of acting. The 50+ diabetes drugs available in the
world in the form of tablets or injection suspension and placed into different
drug’s classes. Below is the list of different classes of drugs used to treat
Biguanides / Metformin
Meglitinides / Prandial glucose
regulator / Glinides
Thiazolidinedione / Glitazones
DPP-4 inhibitors / Gliptins·
Incretin mimetics / GLP-1 analogues
is an epidemic in United
States that is costing lives and money.
The top 10 best-selling diabetes drugs in the USA are·
Human insulin and devices·